LF is not a neglected disease but a priority disease for elimination: Dr. Mandaviya

Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023

The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.

Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US

All claims against the company in the litigation have now been dismissed.

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Lupin's subsidiary MedQuimica acquires rights to nine brands from Bausch Health

The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness

Delivery solution provider ZIM Laboratories Limited lists on NSE

The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.

Dr. Bharti Pawar to participate in Global Conference on Antimicrobial Resistance

The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR

Dr. Lucica Ditiu appreciates India's TB elimination response

Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi

Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules

Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.